Dipeptidyl peptidase 4 inhibitor improves insulin resistance in Japanese patients with type 2 diabetes: a single-arm study, a brief report
Authors:
Open Access
- 7 June 2022
- journal article
- research article
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 14 (1) , 1-6
Abstract
Background: Dipeptidyl peptidase 4 inhibitor (DPP4i) is an effective medicine for type 2 diabetes mellitus (T2DM). Some articles reported DPP4i improves insulin secretion and insulin resistance. However, these effects are not well established by glucose clamp test and test meal in Japanese. We investigated the effect of DPP4i on insulin resistance and insulin secretion by using the glucose clamp test and meal tolerance test (MTT). Methods: We performed a MTT, and the hyperinsulinemic-euglycemic clamp in 8 Japanese patients with T2DM. This study was a single-arm study. We measured fasting and postprandial glucose, insulin, incretins, and glucagon levels. We also measured serum adiponectin levels. Results: HbA1c was significantly decreased after 3 months. The fasting and postprandial glucose levels were significantly decreased. Fasting and postprandial insulin levels were not changed. The insulin resistance derived from the glucose clamp test was significantly improved. HOMA-IR was not significantly changed. GLP-1 and GIP were significantly increased but glucagon did not change. Adiponectin was not significantly changed. Conclusions: Although the number of patients was very small, these results suggested that DPP4i treatment might improve insulin resistance without changing insulin secretion.Keywords
This publication has 24 references indexed in Scilit:
- Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysisDiabetologia, 2013
- 20/(fasting C-peptide × fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary reportCardiovascular Diabetology, 2013
- Measurements of Islet Function and Glucose Metabolism with the Dipeptidyl Peptidase 4 Inhibitor Vildagliptin in Patients with Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2008
- Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usageAmerican Journal of Physiology-Endocrinology and Metabolism, 2008
- Higher levels of adiponectin in American than in Japanese men despite obesityMetabolism, 2006
- Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2006
- Effects of Diet and Exercise on Muscle and Liver Intracellular Lipid Contents and Insulin Sensitivity in Type 2 Diabetic PatientsThe Journal of Clinical Endocrinology & Metabolism, 2005
- GLP-1 Receptor Agonists and DPP-4 Inhibitors in the Treatment of Type 2 DiabetesHormone and Metabolic Research, 2004
- Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2004
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985